Skin sclerosis is only of limited value to identify SSc patients with severe manifestations - An analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register

Rheumatology

Volumn 48, Issue 1, 2009, Pages 70-73

  Hanitsch, L G ^a   Burmester, G R ^a   Witt, C ^a   Hunzelmann, N ^b   Genth, E ^c   Krieg, T ^b   Lehmacher, W ^b   Melchers, I ^d   Meurer, M ^e   Muller Ladner U ^f   Schulze Lohoff, E ^g   Becker, M ^a   Sunderkoetter, C ^h   Riemekasten, Gabriela ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

^g KRANKENHAUS MERHEIM   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Classification criteria; Modified Rodnan skin score; Skin thickness; Systemic sclerosis

Indexed keywords

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; GASTROINTESTINAL SYMPTOM; GERMANY; HEART DISEASE; HUMAN; KIDNEY DISEASE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REGISTER; RODNAN SKIN SCORE; SCLERODERMA; SCORING SYSTEM; SEROLOGY; SKIN ULCER; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

COHORT STUDIES; CONTRACTURE; DEGLUTITION DISORDERS; HUMANS; HYPERTENSION, PULMONARY; PULMONARY FIBROSIS; SCLERODERMA, DIFFUSE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; SKIN ULCER; TIME FACTORS;

EID: 57349145191     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken408     Document Type: Article

References (17)

1. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: A comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989;28:281-6.
2. Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease. Ann Rheum Dis 2001;60:577-84.
3. Furst D, Khanna D, Matucci-Cerinic M et al. Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol 2007;34:1194-200.
4. Clements PJ, Roth MD, Elashoff R et al. Scleroderma Lung Study Group. Scleroderma Lung Study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007;66:1641-7.
5. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
6. The Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
7. Walker UA, Tyndall A, Czirják L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63.
8. Le Roy EC, Medsger TA Jr. Criteria for the classifiation of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
9. Medsger TA Jr. Comment on Scleroderma Criteria Cooperative Study. In: Black CM, Myers AR, eds. Current topics in rheumatology: Systemic sclerosis (scleroderma). New York: Gower Medical Publishing, 1985;16-7.
10. Lonzetti LS, Joyal F, Raynauld JP et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: Addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001;44:735-6.
11. Czirják L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M. Furst DE; EUSTAR. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007;66:966-9.
12. Hunzelmann N, Genth E, Krieg T et al. The registry of the German Network for Systemic Scleroderma: Frequency of disease subsets and patterns of organ involvement. Rheumatology 2008;47:1185-92.
13. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
14. Walker JG, Pope J, Baron M et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007;26:1401-9.
15. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
16. Denton CP, Merkel PA, Furst DE et al. Cat-192 Study Group; Scleroderma Clinical Trails Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323-33.
17. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006;25:205-12.